Cargando…
Re-examining the Meis Trial for Evidence of False-Positive Results
U.S. Food and Drug Administration (FDA)–approved 17α-hydroxyprogesterone caproate therapy is currently available to reduce recurrent preterm birth in the United States. This commentary reviews the original landmark Meis trial (“Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431135/ https://www.ncbi.nlm.nih.gov/pubmed/32769653 http://dx.doi.org/10.1097/AOG.0000000000003991 |